体重指数对托法替布治疗溃疡性结肠炎疗效与安全性的影响:OCTAVE项目分析
该事后分析基于OCTAVE诱导1/2和维持研究,按基线BMI分层评估托法替布治疗溃疡性结肠炎的疗效与安全性。结果显示无论BMI如何,托法替布5或10 mg每日两次均优于安慰剂达到临床应答,BMI不是疗效的显著预测因素,安全性无一致趋势。
要点
- 托法替布5或10 mg每日两次在各BMI亚组均优于安慰剂达到临床应答(所有P<0.05)。
- BMI不是疗效终点的显著预测因素(单变量连续BMI缓解OR 0.98,95%CI 0.95-1.02)。
- BMI≥30亚组接受10 mg每日两次的严重感染数值更高(3.2% vs 其他亚组0.4%)。
核心结论
- 托法替布在溃疡性结肠炎患者中的疗效和安全性在不同基线BMI间相似。
研究设计与样本
- 事后分析评估OCTAVE诱导1和2(8周)及OCTAVE Sustain(52周)研究中接受安慰剂或托法替布的溃疡性结肠炎患者。
- 患者按诱导研究基线BMI分为<25、25至<30和≥30 kg/m²亚组。
主要发现
- 在诱导研究第8周和维持研究第52周,托法替布5或10 mg每日两次组达到临床应答的患者比例高于安慰剂,无论基线BMI亚组(所有P<0.05)。
- 各BMI亚组达到疗效终点的比例总体相似;单变量和多变量回归分析中BMI不是显著预测因素(所有P≥0.05;单变量连续BMI缓解OR 0.98,95%CI 0.95-1.02)。
- BMI与不良事件之间无一致趋势;诱导研究中接受托法替布10 mg每日两次的患者,BMI≥30亚组严重感染数值更高(3.2% vs 其他亚组0.4%)。
关键数值与推荐
- 临床应答:托法替布5或10 mg每日两次 vs 安慰剂,各BMI亚组均P<0.05。
- 缓解:单变量连续BMI OR 0.98(95%CI 0.95-1.02)。
- 严重感染:诱导研究托法替布10 mg每日两次,BMI≥30亚组3.2%,其他亚组0.4%。
临床怎么用
- 托法替布疗效在不同BMI的溃疡性结肠炎患者中相似,BMI不应作为排除托法替布治疗的因素。
- 对BMI≥30且使用托法替布10 mg每日两次的患者,需关注严重感染风险。
局限性
- BMI≥30亚组患者数量少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. AIMS: To assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI). METHODS: This post hoc analysis evaluated patients with UC receiving placebo or tofacitinib from the 8-week OCTAVE Induction 1 and 2 (NCT01465763, NCT01458951) and 52-week OCTAVE Sustain (NCT01458574) studies. Patients were stratified by BMI at OCTAVE Induction 1 and 2 baseline (<25, 25 to <30 and ≥30 kg/m2 ). Outcomes included remission, endoscopic improvement, clinical response, sustained steroid-free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form-36 Health Survey scores. Adverse events were evaluated. RESULTS: At Week 8 of OCTAVE Induction 1 and 2, and Week 52 of OCTAVE Sustain, higher proportions of patients receiving tofacitinib 5 or 10 mg twice daily (b.d.) achieved clinical response vs placebo, regardless of baseline BMI subgroup (all P < 0.05). Proportions of patients achieving efficacy endpoints were generally similar across BMI subgroups; in univariate and multivariate regression analyses, BMI was not a significant predictor (all P ≥ 0.05; univariate BMI [continuous] odds ratio for remission: 0.98 [95% confidence interval 0.95, 1.02]). There was no consistent trend between BMI and adverse events. Among patients receiving tofacitinib 10 mg b.d. in OCTAVE Induction 1 and 2, serious infections were numerically greater in the BMI ≥30 subgroup (3.2%) vs other subgroups (0.4%). Limitations included small patient numbers in the BMI ≥30 subgroup. CONCLUSIONS: Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.
引用
- Farraye FA, Qazi T, Kotze PG, et al. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Aliment Pharmacol Ther. 2021. PMID: 34165201. doi:10.1111/apt.16439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。